ArticleNeuroradiology2026
Distribution of high-resolution magnetic resonance imaging -based carotid Plaque-RADS subtypes among patients with acute cerebral infarction.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe Carotid Plaque Reporting and Data System (Plaque-RADS) is a new quantitative grading system for plaque stability. Herein, high-resolution magnetic resonance imaging (HRMRI)-based Plaque-RADS(HRMRI-Plaque-RADS) classification was performed to characterize the different classifications in patients with cerebral infarction.
methodsHRMRI images from patients with acute cerebral infarction (ACI) of the anterior cerebral circulation were collected retrospectively, and carotid plaques were categorized into the Plaque-RADS 1-4 subtypes. Plaque-RADS 1 and 2 were considered low-risk, and Plaque-RADS 3 and 4 as high-risk. After contrast agent injection, high-risk plaques were further classified as enhanced or non-enhanced. A mixed-effects logistic regression model was applied to identify relationships between plaque types and infarction.
resultsThis study included 98 patients (age 65.6 ± 9.6 years; 88.8% male; 196 carotid arteries). The distribution of Plaque-RADS 1-4 plaques on the infarction side was: 7 (7.1%), 13 (13.2%), 49 (50.0%), and 29 (29.6%), respectively. Among the high-risk plaques, 50 (51%) were enhanced high-risk. The distribution of Plaque-RADS 1-4 plaques on the contralateral side was: 26 (26.5%), 21 (21.4%), 43 (43.9%), and 8 (8.2%), respectively, with 28 (28.6%) high-risk plaques classified as enhanced high-risk. The high-risk and enhanced high-risk plaque types were significantly associated with the infarction side (odds ratio [OR] = 3.71, 95% confidence interval [CI], 1.96-7.05; P < 0.001, after adjustment; OR = 3.05, 95%CI, 1.78-5.23; P < 0.001).
conclusionIn ACI, HRMRI-Plaque-RADS based high-risk and enhanced high-risk plaques were associated with the infarction side. Plaque enhancement offered a supplement to the Plaque-RADS, and HRMRI based Plaque-RADS classification may effectively identify vulnerable plaques.
Indexed as
Identifiers
41240099What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.